Angiogenesis Pathway Gene Polymorphisms for Therapy Selection

Abstract

A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(−251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats.

1 . A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy, comprising screening a suitable cell or tissue sample isolated from said patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(−251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats. 
     
     
         2 . The method of  claim 1 , wherein the anti-VEGF antibody based therapy comprises the administration of a Bevacizumab antibody or its biological equivalent. 
     
     
         3 . The method of  claim 1 , wherein the patient is a cancer patient suffering from a cancer of the group ovarian cancer, lung cancer, breast cancer and colon cancer. 
     
     
         4 . The method of  claim 1 , wherein the cancer treatment further comprises administration of an effective amount of cyclophosphamide. 
     
     
         5 . A method for selecting anti-VEGF antibody based chemotherapy for a patient in need thereof, comprising screening a suitable cell or tissue sample isolated from said patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the therapy is selected if the patient's corresponding genotype is (i) (T/T) for IL-8(251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats. 
     
     
         6 . The method of  claim 5 , wherein the anti-VEGF antibody based therapy comprises the administration of a Bevacizumab antibody or its biological equivalent. 
     
     
         7 . The method of  claim 5 , wherein the patient is a cancer patient suffering from a cancer of the group ovarian cancer, lung cancer, breast cancer and colon cancer. 
     
     
         8 . The method of  claim 5 , wherein the cancer treatment further comprises administration of an effective amount of cyclophosphamide. 
     
     
         9 . A method for treating a cancer patient selected from the group consisting of an ovarian cancer, a lung cancer, a breast cancer and a colon cancer, comprising:
 (a) screening a suitable cell or tissue sample isolated from said patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats),   (b) identifying patients having a genotype selected from the group consisting of (i) (T/T) for IL-8(−251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele containing 14 or more 3′ CA repeats; and   (c) administering an effective amount of an anti-VEGF antibody to the patient identified in step (b), thereby treating the patient.   
     
     
         10 . The method of  claim 9 , further comprising administering an effective amount of cyclophosphamide. 
     
     
         11 . The method of  claim 9 , wherein the anti-VEGF antibody is Bevacizumab or its biological equivalent.